ArticleOncotarget2017

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.

Eric Deutsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.